ARCHIVES

Also in this 8-page issue: Richard Pazdur named director of FDA’s new Office of Oncology Drug Products.

This article is from The Cancer Letter archive.

Vol. 31 No. 16 | April 22, 2005

Download PDF Visit The Full Archive

Related Articles

Three Studies Test Oncotype DX In Breast and Colon Cancers

October 26, 2012

NCI Advisors Approve $100M Set Aside for Physical Sciences-Oncology Centers.

December 12, 2008

Senate Gives NIH Director Authority To Permit Research By Unconventional MDs

September 25, 1992

Dear FDA: Provenge Provokes Letters From Opponents, Advocates, Investors.

April 27, 2007

Pathology Review Confirms Reserpine As Carcinogen

March 14, 1980

Waxman Introduces NIH Reauthorization, Kennedy To Follow

April 26, 1991